RxDoctor Payments Data

Shasank Rijal, MD

Cardiovascular Disease · Everett, WANPI 1093943839

Payments from drug & device makers

$4,486in general payments, 2019–2025

Across 69 payments — averaging $65.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abbott$534
  • Philips North America LLC$501
  • Abiomed$186
  • Shockwave Medical, Inc$167
  • Heartflow, Inc.$133
  • plus $750 from 18 others

What the payments were for

  • Travel & lodging$1,16826%
  • Food & beverage$3,31774%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,486 in reported general payments places this provider in the 75th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington

Medicare billing

Part B allowed, 2024
$224,673
Medicare patients
796
Services billed
2,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$95,481
JardianceEmpagliflozin31$38,525
EntrestoSacubitril/Valsartan35$34,344
Metoprolol Succinate452$5,418
Atorvastatin Calcium235$1,851
Rosuvastatin Calcium181$1,755
Prasugrel Hcl28$1,660
ClopidogrelClopidogrel Bisulfate151$1,582
Flecainide Acetate22$1,542
Losartan Potassium148$1,503
Potassium Chloride69$1,157
Torsemide56$1,081
Digoxin38$1,061
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$925
Furosemide154$913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$39$38,52531 claims
NovartisEntresto$53$34,34435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 370 cardiovascular disease providers in Washington.

Other cardiovascular disease in Everett

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →